Clinical Features and Prognosis of 35 Children with Burkitt Lymphoma/Leukemia.
10.19746/j.cnki.issn.1009-2137.2019.04.021
- Author:
Yong-Zhi ZHENG
1
;
Shao-Hua LE
1
;
Hao ZHENG
1
;
Xue-Ling HUA
1
;
Zai-Sheng CHEN
1
;
Ling ZHENG
1
;
Cai CHEN
1
;
Mei LI
1
;
Chun-Xia CAI
1
;
Jing-Hui YANG
1
;
Yi-Qiao CHEN
1
;
Qin-Li GAO
1
;
Ying-Ying CHEN
1
;
Jian LI
2
;
Jian-Da HU
3
,
4
Author Information
1. Department of Pediatric Hematology, Fujian Provincial Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Provincial, China.
2. Department of Pediatric Hematology, Fujian Provincial Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Provincial, China,E-mail:1354113723@qq.com.
3. Department of Pediatric Hematology, Fujian Provincial Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Provincial, China,E-mail: drjiandahu@
4. com.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Burkitt Lymphoma;
Child;
Child, Preschool;
Female;
Humans;
Male;
Prognosis;
Retrospective Studies
- From:
Journal of Experimental Hematology
2019;27(4):1123-1130
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical features and prognostic factors of childhood Burkitt Lymphoma/leukemia.
METHODS:The clinical data of 35 patients with newly-diagnosed childhood Burkitt lymphoma/leukemia from March 2011 to September 2017 in Fujian Medical University Union Hospital were retrospectively analyzed and summarized. Among 35 patients, 5 gave up treatment and one patient died of multiple organ failure before treatment, and 29 patients received CCCG-BNHL-2010 protocol chemotherapy.
RESULTS:The 35 cases of BL/L includsd 31 males and 4 females (M∶F=7.75∶1) with the median age of 5(2.0-11) years. Clinically, the common infiltration sites were as follows: abdominal organs (especially ileocecus, 21/35, 60%), bone marrow (21/35, 60%), faciomaxillary (10/35, 28.57%), and central nervous system (8/35, 22.85%). According to St. Jude staging system, 6 patients were grouped into stage Ⅱ, and 8 into stage Ⅲ and 21 into stage Ⅳ, among which the bone marrow blasts of 17 patients were more than 25%. The analysis of therapeutic efficacy and prognosis showed that in median follow up of 23.4 (5.3-86.4) months, 5 patients relapsed (5/29, 17.24%), the median relapsed time was 5.7 (3.9-7.2) months; tow-year overall survival (OS) rate and progression-free survival (PFS) rate was 79.2%±7.6% and 78.3%±7.9%, respectively. Univariate analysis showed that the 2-year OS and PFS in patients with LDH＞2N, stage Ⅳ (bone marrow infiltration), central nervous system infiltration and no-CR after 2 courses of treatnent all were significantly lower than those in patients with LDH≤2N, stageⅡ-Ⅲ, without central nervous system infiltration as well as CR after 2 course of treatment (P values were 0.015, 0.015, 0.019 and 0.000, respectively). Cox regression analysis showed that no-CR after 2 course was an independent unfavorable prognostic factor (HR 0.34, 95%CI: 0.03-0.407).
CONCLUSION:The childhood Buruitts lymphoma/leukemia is more freguently seen in males and school-age children, Advanced stage, bone marrow and contral nervous system infitration are common at the first visit to doctor, moreover the Burkitt's lymphoma/leykemia present repid progression and dangerous feature. The current intensive chemotherapy (high dose of drugs and short course) possess the significant therapeutic efficacy for this disease, but the patients should have very poor prognosis if they can not achieve CR after 2 course of chemotherapy.
